Arthur A Levin
Overview
Explore the profile of Arthur A Levin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
2270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andersson P, Burel S, Estrella H, Foy J, Hagedorn P, Harper Jr T, et al.
Nucleic Acid Ther
. 2025 Feb;
35(1):16-33.
PMID: 39912803
Hybridization-dependent off-target (OffT) effects, occurring when oligonucleotides bind via Watson-Crick-Franklin hybridization to unintended RNA transcripts, remain a critical safety concern for oligonucleotide therapeutics (ONTs). Despite the importance of OffT assessment...
2.
Malecova B, Burke R, Cochran M, Hood M, Johns R, Kovach P, et al.
Nucleic Acids Res
. 2023 May;
51(12):5901-5910.
PMID: 37224533
Although targeting TfR1 to deliver oligonucleotides to skeletal muscle has been demonstrated in rodents, effectiveness and pharmacokinetic/pharmacodynamic (PKPD) properties remained unknown in higher species. We developed antibody-oligonucleotide conjugates (AOCs) towards...
3.
Taubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, et al.
Eur Heart J
. 2020 Nov;
42(2):178-188.
PMID: 33245749
Aims: Cardiac microRNA-132-3p (miR-132) levels are increased in patients with heart failure (HF) and mechanistically drive cardiac remodelling processes. CDR132L, a specific antisense oligonucleotide, is a first-in-class miR-132 inhibitor that...
4.
5.
6.
van Poelgeest E, Hodges M, Moerland M, Tessier Y, Levin A, Persson R, et al.
Br J Clin Pharmacol
. 2015 Aug;
80(6):1350-61.
PMID: 26261033
Aims: LDL-receptor expression is inhibited by the protease proprotein convertase subtilisin/kexin type 9 (PCSK9), which is considered a pharmacological target to reduce LDL-C concentrations in hypercholesterolaemic patients. We performed a...
7.
Henry S, Jagels M, Hugli T, Manalili S, Geary R, Giclas P, et al.
Nucleic Acid Ther
. 2014 Aug;
24(5):326-35.
PMID: 25093529
The species sensitivity and mechanism of complement pathway activation by a phosphorothioate oligonucleotide were investigated in monkey and human serum. Increasing concentrations of a phosphorothioate oligonucleotide, ISIS 2302, were incubated...
8.
van Poelgeest E, Swart R, Betjes M, Moerland M, Weening J, Tessier Y, et al.
Am J Kidney Dis
. 2013 Apr;
62(4):796-800.
PMID: 23561896
Antisense oligonucleotides have been explored widely in clinical trials and generally are considered to be nontoxic for the kidney, even at high concentrations. We report a case of toxic acute...
9.
Janssen H, Reesink H, Lawitz E, Zeuzem S, Rodriguez-Torres M, Patel K, et al.
N Engl J Med
. 2013 Mar;
368(18):1685-94.
PMID: 23534542
Background: The stability and propagation of hepatitis C virus (HCV) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 (miR-122). Miravirsen is a locked nucleic acid-modified...
10.
Lindow M, Vornlocher H, Riley D, Kornbrust D, Burchard J, Whiteley L, et al.
Nat Biotechnol
. 2012 Oct;
30(10):920-3.
PMID: 23051805
No abstract available.